Validation of Copy Number Variants Associated with Schizophrenia 
Risk in an Irish Population and Implications to Clinical Practice by Elves, Rachel L
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2013
Validation of Copy Number Variants Associated
with Schizophrenia Risk in an Irish Population and
Implications to Clinical Practice
Rachel L. Elves
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Medical Genetics Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/3197
  
© Rachel Leigh Elves, August 2013 
All Rights Reserved 
  
  
Validation of Copy Number Variants Associated with Schizophrenia  
Risk in an Irish Population and Implications to Clinical Practice 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
 
 
 
 
 
 
 
 
 
by 
 
 
 
Rachel Leigh Elves 
Master of Sciences (M.Sc.) 
University of British Columbia, Canada, 2008 
 
 
Director: Rita Shiang, Ph.D. 
Associate Professor, Department of Human and Molecular Genetics 
 
 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
August 2013
ii 
 
Acknowledgements 
 
I would like to thank my family and friends for their wonderful support, including my parents, 
my husband Rob, and Amy Adkins, Laura Hack, and Jia Yan. A big thank you to my extended 
Richmond family, Ja’Neil Jackson, and Buddy and Nancy Corbett, for looking out for me and for 
giving me great memories to take with me on my journey. Special thanks to my advisors Rita 
Shiang, Sarah Elsea, and John Quillin for all of their help down this long road, and to the Riley 
lab for their help with my project and for the use of their lab space and equipment. 
iii 
 
 
 
Table of Contents 
Acknowledgements ..................................................................................................................................................... ii 
List of Tables ...............................................................................................................................................................iv 
List of Figures .............................................................................................................................................................. v 
Abstract .......................................................................................................................................................................vi 
Chapter 1: Background and Literature Review ....................................................................................................... 1 
Introduction ............................................................................................................................................................... 1 
Neurological and Behavioral Characteristics of Schizophrenia ............................................................................... 1 
Impact on Quality of Life & Society .................................................................................................................... 4 
Genetic Counseling and Estimated Risk ............................................................................................................... 4 
Heritability ............................................................................................................................................................ 5 
Chapter 2: Real Time PCR Validation of Select CNVs in an Irish Population...................................................... 8 
Introduction ............................................................................................................................................................... 8 
Copy Number Variants (CNVs) in the Human Genome ....................................................................................... 8 
CNV Detection and Validation ........................................................................................................................... 11 
Materials and Methods.............................................................................................................................................. 1 
Results ....................................................................................................................................................................... 6 
ISHDSF and ICCSS sample validation of common copy number variant in ERBB4 ........................................... 6 
ICCSS sample validation for rare copy number variants ...................................................................................... 9 
Discussion ............................................................................................................................................................... 12 
Chapter 3: Discussion ................................................................................................................................................ 16 
Current Clinical Practice of Genetic Counseling for Schizophrenia ...................................................................... 16 
Application of CNV-related Risk Estimates in Clinical Practice ........................................................................ 16 
Future of Psychiatric Genetic Counseling .............................................................................................................. 18 
Summary .................................................................................................................................................................. 19 
References .................................................................................................................................................................. 22 
 
iv 
 
 
 
List of Tables 
 
Table 1. Prominent features of subtypes of schizophrenia............................................................. 3 
Table 2. Real-time qPCR assessment of the ERBB4 CNV. ........................................................... 7 
Table 3. ERBB4 deletion frequencies in Irish family and singletons with schizophrenia compared 
to North American and Irish controls. ............................................................................................ 8 
Table 4. Potential CNV risk loci for schizophrenia validated by qPCR in an Irish case-control 
sample. .......................................................................................................................................... 10 
 
 
 
 
 
  
v 
 
 
 
List of Figures 
 
Figure 1. UCSC genome browser custom track (hg18 assembly) showing Taqman probe location 
for qPCR validation of ICCSS samples with putative CNVs. ........................................................ 5 
Figure 2. CHD1L, COX5B, PAK7, and ZFYVE20 CNV validation of Birdseye calls by VCU 
and Dublin groups in ICCS sample using Taqman qPCR ............................................................ 11 
  
vi 
 
 
 
Abstract 
 
VALIDATION OF COPY NUMBER VARIANTS ASSOCIATED WITH SCHIZOPHRENIA  
RISK IN AN IRISH POPULATION AND IMPLICATIONS TO CLINICAL PRACTICE 
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A dissertation submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2013 
 
Director: Rita Shiang, Ph.D. 
Associate Professor, Department of Human and Molecular Genetics 
 
 Schizophrenia is a complex disorder affecting 1% of the population and is highly 
heritable, but the majority of contributing genetic factors has remained elusive. Current risk 
estimates for clinical practice are primarily determined by family history and associated 
empirical risk. Copy number variants (CNVs) may hold the key to explaining the missing 
vii 
 
 
 
heritability in schizophrenia research; schizophrenia risk estimates as high as 30% have been 
found for the most-studied CNV associated with schizophrenia, 22q11.  
Currently, there are methods to identify CNVs though previously collected data from 
SNP microarrays that would facilitate these types of studies. To determine if algorithms that call 
CNVs from microarray data are robust four genomic regions with putative CNVs called by the 
Wellcome Trust Consortium using Birdseye in Birdsuite with Affymetrix 6.0 array raw SNP 
intensities, primarily affecting genes CHD1L, COX5B, PAK7, ZFYVE20, were validated using 
Taqman real-time qPCR assays in 29 samples by research groups at VCU and Dublin. CNVs 
called from the algorithm were 100% validated at VCU though there were false negatives from 
the algorithm that were validated. Two samples at loci with putative duplications were not called 
by the Dublin group, which may be because of differing sensitivities of the Taqman assays to be 
able to detect a 50% difference in copy number between duplications and diploid controls, or 
because of another technical or analytical difference between the two sites.  
 Deletion frequency of one common CNV found in the gene ERBB4, was assessed by 
qPCR in both Irish singleton (ICCSS) and Irish family (IHDSF) samples and compared with 
Irish control (Trinity Biobank) and North American control populations. The ERBB4 deletion 
frequency was not significantly different when comparing the Irish controls to the Irish singleton 
or the Irish family samples though the family samples were different when compared against the 
North American control population, which suggests population stratification, rather than a true 
association between ERBB4 and increased schizophrenia risk. 
Current clinical practice has been improved by knowledge and evaluation of CNV-related 
disorders that include risk for psychosis and additional phenotypes. Genotyping of individuals 
with known psychosis has led to improved patient care for non-psychosis-related phenotypes 
viii 
 
 
 
associated with CNVs. Individuals with suspected genomic disorders that are found to have 
CNVs can be counseled on potential psychosis risk and potential risk to their offspring. 
Recurrent CNVs may hold promise in future clinical practice in order to individualize risk 
estimates in the general patient population, and increase the number of individuals able to 
receive anticipatory treatment to minimize disease severity.  
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Chapter 1: Background and Literature Review 
Introduction 
Schizophrenia is a complex neurodevelopmental disorder that strikes in the prime of life 
between the ages of 18 and 35, and affects as many as 24 million individuals worldwide
1,2
. Up to 
50% of individuals are not receiving adequate treatment for their symptoms
3
 that can include: 
hallucinations, delusions, disorganized speech and behavior, and catatonia
1
. Perhaps more 
concerning is negative symptoms, like flattened mood, loss of motivation, and reduced or absent 
speech. Negative symptoms are resistant to treatment and can lead to withdrawal from society
3
. 
This effect is compounded by the stigma faced by individuals resulting in isolation and potential 
worsening of symptoms
2,3
.  
 
Neurological and Behavioral Characteristics of Schizophrenia 
Schizophrenia is a spectrum of disorders rather than a single disorder and can vary 
greatly in severity and specific symptoms between individuals
4
. The Diagnostics and Statistical 
Manual IV-R outlines that a clinical diagnosis of schizophrenia can be made if an individual has 
two or more of the following active symptoms that are present for a significant amount of time 
over the period of a month:  delusions; hallucinations; disorganized speech; disorganized or 
catatonic behavior; and negative symptoms. If delusions are considered to be bizarre, or if 
hallucinations involve a voice keeping running commentary on a person’s thoughts or behavior, 
or involve two or more voices conversing with each other, only one of the above symptoms need 
to be present for a diagnosis.  
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Negative symptoms are a loss of normal abilities and/or behavior. They usually 
contribute to poorer prognosis, and are generally more resistant to treatment. These can include:  
 Alogia: inability to speak 
 Affective flattening: loss or lack of emotional expressiveness, where one acts neither 
depressed nor happy 
 Avolition: lack of motivation or drive, an individual is unable to pursue personally 
meaningful goals 
Schizophrenia is divided into 5 clinical subtypes. An individual cannot be diagnosed with 
more than one subtype. Undifferentiated type is a diagnosis used when an individual does not 
meet the criteria for any of the other four subtypes.  
 
Paranoid type: Characterized by frequent and persistent auditory hallucinations, or one or more 
delusions. Disorganized speech, disorganized behavior, and flat/inappropriate affect are minimal. 
 
Disorganized type: Centered on disorganized speech and behavior, as well as flat/inappropriate 
affect. 
 
Catatonic type: Major distinctive features include 2 or more of the following: 
 Stupor/immobility 
 Excessive and purposeless motor activity 
 Echolalia or echopraxia (parroting words or movements of another person). 
 Extreme negative symptoms with: 
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o Resistance to following instructions, remaining rigid while others attempt to move 
you, or mutism 
o Voluntary movement peculiarities like noticeable grimacing, assumption of 
bizarre poses, stereotyped movements, and prominent mannerisms 
 Abnormal voluntary movements: 
o Posturing (holding an unusual pose) 
o Noticeable grimacing 
o Stereotyped movements 
o Prominent mannerisms 
 
Undifferentiated type: A subtype in which the individual meets the diagnostic criteria for 
schizophrenia, but the pattern of prominent symptoms is not characteristic of residual, paranoid, 
catatonic, or disorganized type. 
 
Residual type: Defined by a lack of prominent delusions, hallucinations, catatonic behavior, 
disorganized behavior, or disorganized speech. Continued evidence of the underlying disorder is 
displayed in the form of negative symptoms, or 2 or more other symptoms with a milder 
phenotype (e.g. odd beliefs, unusual perceptual experiences). 
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Table 1. Prominent features of subtypes of schizophrenia. 
 
 Schizophrenia Subtypes 
Possible Symptoms Paranoid Disorganized Catatonic Undifferentiated Residual 
Delusions  — — — — 
Hallucinations  — — — — 
Disorganized speech —  — — — 
Disorganized/ 
catatonic behavior 
—   — — 
Negative symptoms —   —  
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Impact on Quality of Life & Society 
Suicide is a major risk factor, especially for young men
3
. It is a major contributory factor 
to the 15 year decrease in life expectancy among the population with schizophrenia
3
. Life span is 
further reduced by 10 years in the approximately 9-16% of the population with schizophrenia 
who will become homeless
3
. African Americans with schizophrenia have a greater risk of 
homelessness than other major ethnic groups in the United States, most of whom will have 
difficulty navigating the health system
3
. Disorganization and lack of income increases 
proportionally with disease severity; this is compounded with poor access to community housing 
and support services to create an environment where 48% of these individuals are not receiving 
care for mental health and the other chronic conditions they might have
3
. 
 
Genetic Counseling and Estimated Risk 
Improved outcomes for people with schizophrenia can be achieved with early diagnosis, 
which can limit the severity and progression of disease
2,5
, and through education of the genetic 
nature of the disease to help reduce stigma and improve societal and familial support for this 
vulnerable population
2,3,6,7
. Common population susceptibility alleles for schizophrenia are 
thought to be numerous, but the exact number and type of genetic variants is poorly understood
8
. 
It is thought that a subset of genes cause disease in individuals, so that any single susceptibility 
gene is neither necessary nor sufficient for causing disease. With heritability estimated to be 73-
90%
2
 the hope is to be able to identify possible high risk variants, or panels of small risk variants 
that put individuals at increased risk of developing schizophrenia
2,7,9
. In this way, the necessary 
social, familial, and medical supports and resources can be put in place before onset or early 
during onset of the disease to minimize negative outcomes
3,7
.  
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This vulnerable and underserved population of individuals and their families need health 
professionals well-versed in technical, familial, and societal implications of schizophrenia
2,3
. 
Genetic counselors have long applied themselves to disease risk estimation, coordination of 
medical and social supports, and educational outreach
2
. Current psychiatric risk is evaluated 
using known disease associations and empirical evidence applied to the incidence and 
relatedness of schizophrenia and related neurodevelopmental disorders within a family
2
. Adding 
individual and/or family risk variant information has the potential to revolutionize the field of 
psychiatric genetics
2,7
, as maternal serum screening has transformed the field of prenatal 
genetics. 
 
Heritability 
Schizophrenia is a complex disorder thought to involve multiple genes and the 
environment with heritability estimated between 73-90%
1,8,10
. About 60% of schizophrenia cases 
are sporadic with no affected first or second degree relatives 
11
. Risk relative to the population 
increases with closer and increased numbers of affected relatives with up to 50% risk for 
individuals with an affected monozygotic twin
12
. Having a first degree relative poses an 
individual risk of 6% if one has a parent with schizophrenia, and up to 17% if one has a fraternal 
twin with schizophrenia. This large range of risk amongst individuals with the same relatedness 
to those with disease illustrate the environmental component to schizophrenia risk, which may 
include uterine environment, generational differences, social environment, and the family 
environment
13
. Although highly heritable, gene finding efforts for schizophrenia using family-
based linkage analysis and the candidate gene approach have so far met with limited success
14
.  
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Great hope was put in genome wide association studies (GWAS) to find risk variants for 
complex diseases like schizophrenia
9
. Focusing on single nucleotide polymorphisms (SNPs) 
researchers struggled to find the power to detect the many variants contributing to heritability 
that were thought to be found in low frequency and/or have a small effect on total disease risk
9,15
. 
Some of the limited number of loci with replicated results include: ZNF804A, which encodes a 
zinc finger transcription factor
16
; an upstream SNP of the NRGN that encodes a postsynaptic 
protein kinase
16
; and TCF4, a gene involved in cognitive function
16
. In recent years we have seen 
the culmination of multiple GWAS with increased power made possible by including large 
numbers in study and control groups, and the meta-analysis of these studies. Three separate 
groups have found associations in the major histocompatibility complex region on chromosome 
6p21.3-22.1
16,17
, which contains genes related to immunity, cognition, memory, and brain 
development
17
. The outcomes of these studies have helped build knowledge of the components 
of heritability of schizophrenia, but have only explained a small portion, as low as 6%
15
, of the 
total estimated 80% heritability of schizophrenia. 
More focus started to be put on copy number variants (CNVs) as an alternative for 
explaining the missing heritability in schizophrenia and related multifactorial 
neurodevelopmental diseases
9
. The typical number of copies of a genomic region is two, one 
maternal copy and one paternal copy. CNVs may be present as deletions where only one copy, or 
zero copies are present; or as duplications, where two or more copies of a genomic region are 
present. CNVs are one of the most common sources of variation making up 13% of the human 
genome, and an estimated 1000 CNVs in the average person
18
. CNVs have a wide range of 
physical size (hundreds – millions of base pairs) and may carry small or large risk for a specific 
disease or group of diseases. By studying risk effects of single CNVs and groups of CNVs, 
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genetic counselors and the medical community will gain an important tool to help improve and 
personalize risk estimates in order to facilitate early diagnosis and minimize negative disease 
outcomes.   
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Chapter 2: Real Time PCR Validation of Select CNVs in an Irish Population 
Introduction 
Copy Number Variants (CNVs) in the Human Genome 
CNVs are localized duplication or deletion events that are thought to be caused mainly by 
nonallelic homologous recombination (NAHR), nonhomologous end-joining, or fork stalling and 
template switching (FoSTeS)
19,20
. NAHR is thought to be the most frequent cause of CNV 
formation and involves two regions of the genome that share low copy repeats (LCRs) that pair 
up and recombine during meiosis or mitosis
20
. If the two LCRs are in the same 5’ to 3’ 
orientation and are located on the same chromosome the result is a duplication and/or deletion in 
progeny cells. For efficient NAHR, LCRs must share minimal efficient processing segments 
(MEPS) – highly similar sequences that are typically 300 – 500bp, vary in length requirements 
depending on the involved loci, and can differ between meiotic and mitotic events. Certain 
regions of LCRs are genomic hotspots for NAHR, which explains the clustering of breakpoints 
and similar size of recurrent CNVs across multiple individuals. These regions often have features 
than can induce double-strand breaks, such as palindromes or minisatellites. Non-recurrent, rare 
CNVs can be mediated by NAHR through Alu and LINEs (long interspersed elements) and can 
result in clustering of breakpoints of CNVs. These rare CNVs may share one or more smallest 
region of overlap (SRO) across individuals, which can be used to investigate the association of 
specific SROs and any gene(s) contained within them with disease. In addition, some non-
recurrent CNVs may have grouping of one breakpoint within a small genomic region across 
individuals, which may reflect the presence of genomic regions capable of double strand breaks. 
Non-homologous end-joining (NHEJ) is normally used as one of the main mechanisms to 
repair double-strand DNA breaks but can also cause translocations in cancer, severe-combined 
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immunodeficiency through inherited NHEJ defects, or small CNVs
20
. After a double-strand 
break occurs and is detected, the break is bridged molecularly and the ends of the break are 
modified to make them compatible before repair of the break through ligation. Modification of 
the broken ends can involve the deletion or addition of several nucleotides, which has the 
potential to contribute to disease risk if located within a gene or another important genomic 
sequence. 
FoSTeS is thought to be induced by repetitive sequences, palindrome, stem-loop 
structures, and other genomic features that cause DNA polymerase II to stall, which can cause 
the lagging replication strand to disengage and anneal with a new replication fork through 
microhomology
20
. Once DNA synthesis restarts, the invading strand primes its own template-
based extension at the new fork. Multiple FoSTeS events can occur consecutively, which can 
result in complicated arrangements of sequences with a mixture of duplications and deletions in 
direct and/or inverted orientation to the original sequence. 
 
Hypothetical Mechanisms of Disease 
CNVs caused by the above mechanisms can encompass a portion or all of a gene, many 
genes, or no known genes
19
. While change in copy number can be relatively benign, change in 
copy number at certain loci in some individuals can cause or increase risk for disease through a 
number of different mechanisms such as gene position effects, gene disruption, gene dosage, and 
gene fusion events
19
. CNVs have been implicated in Mendelian diseases, such as DiGeorge 
syndrome, as well as complex multifactorial diseases like autism, intellectual disability, and 
schizophrenia
21
.  
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Compared to controls, the overall number of CNVs has been shown to be increased in 
individuals with schizophrenia
22
. The International Schizophrenia Consortium found that rare 
CNVs that were greater than 100 kb and found in less than 1% of their sample were increased in 
number by 1.15-fold in individuals with schizophrenia compared to controls
8
. When taking genic 
content into account the difference in number of CNVs between cases and controls was 1.41-
fold
8
. Affymetrix 5.0 SNP array genome wide scans of a study using trios of schizophrenia cases 
and controls showed an 8-fold increase of de novo CNVs in sporadic cases compared to 
controls
23
. Inherited CNVs were elevated by 1.5-fold in sporadic cases compared to controls
23
. 
This effect is more pronounced with CNVs that are both rare (<1%) and large (>1 Mb). These 
deletions and duplications were elevated 2.26-fold in cases vs. controls and up to 4.53-fold in 
cases when including only deletions
24
. 
 
CNV Risk Loci in Schizophrenia 
A small number of rare, recurrent CNV loci have shown evidence of association with 
schizophrenia, including deletions at 1q21.1, 15q11.2, 15q13.3, and 22q11.2
8,17,22,24
. Other less-
replicated CNV loci associated with schizophrenia risk include the 3q29 deletion, 16p11.2 
duplication, 16p13.11 duplication, and 17q12 deletion
8,17,21,22,24
. Some of these CNVs have large 
effect sizes
25
 including up to a 30% risk of schizophrenia for 22q11 deletion
21
. 
Common CNVs may also contribute to schizophrenia risk but are thought to have a 
smaller average effect size on disease risk compared to rare variants
21
. The current predominant 
hypothesis is that the mechanism for development of schizophrenia is most likely a combination 
of both rare and common CNVs, other genetic variants, and environmental factors
25
.  
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Individuals with schizophrenia carrying the most-studied risk conferring CNV, the 
22q11.2 deletion, are clinically indistinguishable in terms of schizophrenia diagnosis from those 
who do not carry the deletion. The frequency of the 22q11.2 deletion in the general population is 
about 1/3,000 - 1/6,000 live births
6,13
, while the frequency in the population with schizophrenia 
is about 1%
13
. On average, approximately 90-95% of deletions are de novo, and 5-10% are 
inherited, with affected family members showing variable expressivity and differing clinical 
features
6,21,26,27
. In clinical settings transmission is often seen through mothers with mild 
neuropsychiatric phenotypes
6
. Risk of schizophrenia with a 22q11 deletion is about 25-30%, and 
individuals with 22q11 deletion account for about 1% of the population with schizophrenia 
making the 22q11 deletion the variant with the largest risk effect size discovered to date for 
schizophrenia. 
The 22q11 deletion can cause highly variable phenotypes. Common features include cleft 
lip/cleft palate, intellectual disability, developmental delay, seizure, immunodeficiency, and 
congenital heart defects
13,26,27
. Most cases discovered to date have similar microdeletions 3 Mb 
in length and the high recurrence rate of these mutations may be related to low-copy repeats that 
predispose this region to rearrangements
13
. Most of the deletions seen at this locus are thought to 
originate from non-allelic homologous recombination events
6
. Genetic background and 
environmental factors likely play a role in the observed variable phenotypes in individuals with 
similar or even identical deletions. 
  
CNV Detection and Validation 
The three main methods of CNV detection are comparative genomic hybridization, using 
raw SNP intensities from GWAS SNP array, and direct sequencing
28-30
. Comparative genomic 
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hybridization was long considered to be the gold standard for CNV detection, but there is 
significant cost involved. Using algorithms to call raw CNVs from GWAS SNP arrays is being 
increasingly used in research settings, because it is currently the most cost effective method and 
because SNP intensity data is often freely available from previous GWAS studies
28,29
. This study 
aims to explore feasibility of calling CNVs from SNP intensity data in terms of accuracy and 
validity of calls, and whether follow-up validation with real-time qPCR is necessary. 
 
CNV Detection Algorithms using Single Nucleotide Polymorphism DNA Microarray 
 CNV detection algorithms attempt to determine locations of CNVs in an individual’s 
genome by looking for changes in sets of sequential SNP fluorescent probe intensities along a 
chromosome, often 10 probes or more in length
28-30
. A putative CNV region will have a 
decreased probe intensity for deletions (approximately 50% decrease for single copy, very low or 
non-detectable signal intensity for zero copy), and increased probe intensity for duplications 
(150% for three copies), compared to the surrounding probe intensities in the putative non-CNV 
(diploid) region. Duplications greater than three copies in number become more difficult to 
ascertain exact copy number because the difference in the increase in probe intensity becomes 
smaller with increasing copy numbers. 
 SNP probe intensities vary according to genomic location, quality of the probe design, 
and between technical and biological replicates, which can result in a higher false positive rate 
and possibly a higher false negative rate compared to the other methods of CNV detection
28-30
. A 
number of studies have tried to address specificity and sensitivity of CNV calls using SNP 
intensities by using multiple calling algorithms. While this may reduce the false positive rate, the 
sensitivity may be severely reduced. Specific algorithms like PennCNV are thought to call CNVs 
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much more conservatively than other algorithms, which would reduce the amount of overlap 
seen between multiple algorithms
30
. In certain cases, such as CNVs less than 10 kb in size it may 
be preferable to require the agreement between two or more algorithms before making a CNV 
call.  
Although some progress has been made in improving CNV calling through these 
algorithms it is still currently necessary to follow up putative CNV loci with validation through a 
method like quantitative real-time PCR, especially if a particular locus has not been previously 
identified in the literature. This study analyzed CNVs from an Irish case control and family 
sample to further evaluate the utility of CNV-based risk analysis for schizophrenia using 
microarray SNP intensity algorithm calls. 
 Some of the CNVs evaluated in this study that have prior evidence for association with 
schizophrenia include regions encompassing chromodomain helicase DNA binding protein 1-like 
(CHD1L), p21 protein (Cdc42/Rac)-activated kinase 7 (PAK7), and v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 4 (ERBB4). CHD1L is located at 1q21.1, where 
changes in copy number have been associated with schizophrenia, intellectual disability, autism, 
dysmorphic features, congenital heart anomalies, or a normal phenotype with no detectable 
clinical abnormalities
31
. Both duplications and deletions are present in this region that includes at 
least 12 genes, including CHD1L. Harvard et. al.
31
 showed a correlation between RNA and 
protein expression and CNVs at CHD1L. Reduced CHD1L in lymphoblast cell lines was shown 
to interfere with a cell cycle checkpoint, and resulted in elevated levels of pseudomitotic cells 
that exhibited entangled chromatids. This phenotype is similar to that seen in Werner syndrome, 
which predisposes individuals to premature aging and cancer. 
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 Although not statistically significant, two studies found PAK7 duplications in 
schizophrenia cases only and not in controls
32
. PAK7 is a Ser/Thr protein kinase expressed 
predominantly in the brain, which is implicated in regulation of cell proliferation, survival, and 
signaling, as well as cytoskeletal dynamics
33
. It may provide a role in neurite development by 
promoting neurite outgrowth. 
 A common CNV has been observed in intron 1 of ERBB4. ERBB4 is a receptor for 
neuregulin, a ligand potentially involved in glutamatergic synapse plasticity and NMDA receptor 
hypofunction in schizophrenia
34
 . This is hypothesized to influence the onset of positive 
symptoms like hallucinations and may be precipitated by stress. A number of candidate gene and 
association studies have provided support for an association between neuregulin and 
schizophrenia risk, and ERBB4 has been linked with increased risk for childhood 
schizophrenia
32,35
.   
 Cytochrome c oxidase subunit Vb (COX5B), and zinc finger, FYVE domain containing 20 
(ZFYVE20) genes have been implicated in psychiatric and neurodevelopmental disorders such as 
depression and autism. Rat studies looking at the oxidative phosphorylation pathway showed that 
COX5B may provide a protective effect against stress. Rats resilient to experimental stressors 
had significantly up-regulated COX5B expression. It has been hypothesized that susceptibility to 
stress plays a major role in the development of unipolar depression and post-traumatic stress 
syndrome, and some studies have linked stress susceptibility to development of schizophrenia as 
well
36-38
. 
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Materials and Methods 
Study Populations 
CNVs were studied using the Irish Case Control Study of Schizophrenia sample (ICCSS) 
(n=1021 cases)
39
 and Trinity Biobank Irish controls (n=2000 controls). A common CNV in 
ERBB4 was evaluated using the aforementioned case and control samples, as well as the Irish 
Sample of High Density Schizophrenia Families (ISHDSF) (n=270 families, n=1426 
individuals). Affected status in both ICCSS and ISHDSF was established using DSM-IIIR 
criteria
39
 from in-patient and out-patient facilities in Northern Ireland and Ireland. ISHDSF were 
ascertained through Irish probands that had one or more additional family member affected with 
schizophrenia, or schizoaffective disorder. Data from North Americans of European descent 
were obtained from the Children’s Hospital of Philadelphia (CHOP) by Shaikh, Gai, Perin, et. 
al
40
. 
 
CNV Calling from SNP Arrays 
Putative CNVs were called in n=1021 ICCSS cases and n=2000 Trinity Biobank controls 
run on Affymetrix version 6.0, 900k SNP array from SNP intensities using Birdseye in Birdsuite 
(v 1.5.5). ISHDSF CNV calls were generated from PennCNV from Illumina 610 Quad array 
SNP intensities using select Irish Sample of High Density Schizophrenia Families (ISHDSF) 
samples that were independent from one another (family founders), n=107 
41
.  
Samples were excluded that had failed SNP quality control and where SNP call rate was 
<0.95. Calls were excluded from sex chromosomes; where putative CNV lengths were >10Mbp 
or <100kbp; and where the putative CNV had ≥50% overlap with a region that had CNVs in 
≥1% of samples. 
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Putative CNV Locus Selection for Validation/Evaluation 
The top CNVs from ICCSS and Trinity Biobank called by the Wellcome Trust, as chosen 
by locus significance and recurrent CNV loci, were selected for validation at VCU and Trinity 
College Dublin (TCD) through real-time quantitative PCR. Regions selected using genome build 
hg18
42
 include: chromosome 2cen – q13, 97-98Mb (COX5B); chromosome 1q12, 144 – 147Mb 
(CHD1L); chromosome 3p25.1, 15.05 – 15.2Mb (ZFYVE20); and chromosome 20p12, 9 – 10Mb 
(PAK7). A putative common CNV at chromosome 2, 211 – 213Mb (ERBB4) was selected based 
on previous association with schizophrenia, and a possible over-representation in ISHDSF family 
founders compared to CHOP North American controls in the literature (n=2640)
40
. ERBB4 
deletion frequency was also assessed in ICCSS (n=462) and Trinity Biobank samples (n=448) 
using real-time qPCR. 
 
Real-Time Quantitative PCR Validation of Putative CNVs 
Invitrogen Taqman probes were chosen using the smallest region of overlap shared 
between all samples within a putative CNV region for which a pre-designed Taqman probe was 
available (Figure 1). All DNA samples for cases and controls were quantified using Nanodrop 
(Thermo Scientific) and transferred to Bio-Rad 200μL 96-well plates, where each sample 
concentration was adjusted to within 50 – 55 ng/μL using DNA sample buffer. Working plates of 
5 – 6 ng/μL DNA were made using the Eppendorf epMotion 5075 robot on ABI Prism 384-well 
clear optical reaction plates. One blank (DNA suspension buffer) and one CEPH control sample 
(Coriell Institute for Medical Research) were included on each working plate.  
  
3 
 
PCR reactions are set up using the Eppendorf epMotion 5075 robot with 50 μL 
Eppendorf epTIPS Motion pipette tips and 2 μL of 5 – 6 ng/μL DNA and 8 μL of PCR reaction 
mix containing ABI Taqman primer mix for the specific gene being tested, ABI RNase P 
Taqman primer mix (internal standardization control), Taqman reaction mix, and DNase and 
RNase free distilled water. Quadruplicate samples were then run using templates called for 
CNVs on the ABI 7900HT fast real-time PCR system machine.  
Quantitative real-time PCR reactions were analyzed using SDS software (Applied 
Biosystems) with a CT threshold of 0.2, and quantification data from SDS was exported as a tab-
delimited text file and imported to Copy Caller in this format. For each sample, Copy Caller 
determined a confidence interval for copy number and then assigned a best full integer estimate 
for copy number. Copy number calls were normalized to the average of the most common copy 
number variant present at the locus in the samples analyzed. Samples with copy number 
confidence scores below 0.84 were excluded from further analysis. ISHDSF data was provided 
courtesy of Erik Loken. 
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Figure 1. UCSC genome browser custom track (hg18 assembly) showing Taqman probe 
location for qPCR validation of ICCSS samples with putative CNVs. Red bars: subjects with 
putative deletion CNVs. Green bars: subjects with putative duplication CNVs. Known UCSC 
genes are shown below putative CNVs (http://genome.ucsc.edu)
42
.   
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Results 
ISHDSF and ICCSS sample validation of common copy number variant in ERBB4 
A common deletion variant in ERBB4 was found to have an elevated frequency in the 
ISHDSF sample using PennCNV on SNP intensities from microarray data on select samples 
(Tables 2-3). PennCNV calls were validated using Taqman quantitative real-time PCR and 
showed that the frequency in independent family founders was 9.8% (n=107) (courtesy Erik 
Loken), which was increased compared to 4.5% in North American Caucasians (Children’s 
Hospital of Philadelphia sample) (chi-sq=12.2, p=0.0005) (Table 2). The ICCSS case sample and 
the Trinity Biobank Irish control sample were used to rule out the possibility of population-
specific frequencies of the ERBB4 deletion variant. Table 3 summarizes the ERBB4 deletion 
frequencies found in the samples used. Taqman qPCR validation showed that there is an increase 
in deletion variant frequency in Irish controls (7.7%, n=448) compared to North American 
Caucasians (4.5%). No significance difference was found when comparing the deletion 
frequency in Irish Family Founders to population matched controls (chi-sq=1.0, p=0.31), or Irish 
cases (6.6%, n=462) to population controls (chi-sq=0.8, p=0.36). 
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Table 2. Real-time qPCR assessment of the ERBB4 CNV.  
 
 
 
 
 
 
*Calculated copy number calls with confidence scores <0.84 were excluded. **IHDS Family data 
courtesy Erik Loken. 
  
 
 
  
Predicted Copy 
Number 
ICCSS 
Cases 
Trinity Biobank 
Controls 
IHDS Family 
Founders** 
0 1 2 0 
1 59 65 21 
2 400 381 86 
3 1 0 0 
4 0 0 0 
5 1 0 0 
Total Analyzed* 462 448 107 
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Table 3. ERBB4 deletion frequencies in Irish family and singletons with schizophrenia compared 
to North American and Irish controls. 
 
Sample Deletions (%)* Non-Deletions 
Independent Family
41
** 21 (9.8%) 193 
North American Caucasian
40
 118 (4.5%) 2522 
Irish Singleton Cases 61 (6.6%) 863 
Irish Population Controls
39
 69 (7.7%) 827 
 
Irish Cases vs. Irish Controls χ2df=1= 0.032, p=0.858. Family vs. Irish Controls χ
2
df=1
 
=0.321, 
p=0.571. *Calculated copy number calls with confidence scores <0.84 were excluded. **IHDS 
Family data courtesy Erik Loken. 
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ICCSS sample validation for rare copy number variants 
Four rare CNVs called by the Wellcome Trust Consortium
39
 were validated using 
Taqman real-time qPCR in 29 samples. Each sample contained a single CNV in one of the loci 
evaluated: CHD1L (1q12), COX5B (2cen-q13), PAK7 (20p12), ZFYVE20 (3p25.1) (Table 4, 
Figure 2). The Birdseye in Birdsuite algorithm called 1 duplication at COX5B and no CNVs at 
the other 3 loci in Irish Biobank controls. Birdseye called 7 CNVs at CHD1L, 12 CNVs at 
COX5B, and 5 CNVs each at ZFYVE20 and PAK7 loci. All four loci showed locus-specific 
higher rates of CNVs in cases compared to controls, but none of these loci except for COX5B 
achieved genome-wide significance (Table 4). 
These samples were concurrently validated, using separate qPCR assays, by the Dublin 
group (Table 6). Validations performed at VCU and Dublin were in agreement except for two 
samples, and each of the four CNVs was validated at the selected loci. The calls not in agreement 
were: a COX5B duplication found in a Biobank control sample validated at VCU, C0822, was 
not validated by Dublin; and case sample 5301-801, where the VCU group found a duplication 
and the Dublin group found no CNV. VCU and Dublin found a CHD1L deletion in one sample 
where Birdseye found no CNV. 
  
  
10 
 
Table 4. Potential CNV risk loci for schizophrenia validated by qPCR in an Irish case-control sample. 
Name  Symbol  Position* CNV Size  # Cases # Controls 
Broad** Dup/Del Significance 
Level  
Chromodomain 
helicase DNA binding 
protein 1-like 
CHD1L  1q12  146.7 
Mb   
258kb – 
2143kb  7 0 
Locus P: 0.0125399 
GW P: 0.446036 
Cytochrome c oxidase 
subunit Vb  
COX5B  2cen-q13  98.3 Mb  101kb – 
391kb  
12 1 
Locus P: 0.000299997 
GW P: 0.00805992 
Zinc finger, FYVE 
domain containing 20 
ZFYVE20  3p25.1  15.1 Mb  110kb – 
125kb  
5 0 
Locus P: 0.0444796 
GW P: 0.943271 
 p21 protein 
(Cdc42/Rac)-activated 
kinase 7 
PAK7  20p12  9.5 Mb  142kb – 
149kb  5 0 
Locus P: 0.0433896 
GW P: 0.943271 
 
*Genomic positions based on hg18 assembly. ** Broad schizophrenia spectrum: includes all disorders that significantly aggregated in 
relatives of schizophrenic probands in the Roscommon Family Study
43
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Figure 2. CHD1L, COX5B, PAK7, and ZFYVE20 CNV validation of Birdseye calls by VCU 
and Dublin groups in ICCS sample using Taqman qPCR. Rare CNVs were called from 
Affymetrix 6.0 SNP intensities using Birdseye in Birdsuite CNV calling algorithm. Green: CNV 
duplications. Red: CNV deletions. Yellow: No discernible CNV. White: Sample not tested*. 
*Specific samples were unavailable for testing at VCU due to low amount of DNA available. 
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Discussion 
Four rare CNVs called by the Wellcome Trust Consortium using Birdseye in Birdsuite 
with Affymetrix 6.0 array raw SNP intensities, CHD1L, COX5B, PAK7, ZFYVE20, were 
validated using distinct Taqman real-time qPCR assays in 29 samples at VCU and Dublin, and 
were in agreement except for two samples. The lack of agreement could be because of the 
difference in Taqman probes used between the two groups: the probes may have different 
properties affecting PCR efficiency that may have made the select Taqman qPCR assays used by 
the Dublin group less sensitive to detecting duplications than the comparable qPCR assays used 
by the VCU group. In addition, there were technical issues regarding the age and quality of DNA 
samples that required repeated and careful titration to ensure the DNA of the samples and 
controls used were of near equal concentrations. Detection of duplications can be more sensitive 
to small deviations in DNA concentrations, since the goal is to detect a 50% difference in copy 
number compared to diploid controls. Detection of deletions can tolerate a greater deviation in 
DNA concentration amongst samples, since there is a two-fold difference in copy number 
compared to diploid controls; all of the putative deletion CNVs were in agreement between the 
VCU and the Dublin group. Validation could be repeated at both sites using both sets of Taqman 
assays for each locus, which would show whether the discrepancies in calls were the result of 
differing Taqman assay sensitivities, or because of some other technical or analytical difference 
between the two sites.  
VCU and Dublin called a CHD1L deletion that Birdseye called as regular copy number 
(diploid). This appears to be a false negative, since qPCR is a more robust method of CNV 
detection, and because the call was in agreement at two separate sites performed with two 
separate qPCR assays. False negative calls such as these cause a reduction in analytical power 
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that can make it more difficult to achieve genome-wide significance for true differences in 
frequencies between affecteds and controls. An additional difficulty is power reduction due to 
the small effect sizes typically seen with CNVs associated with schizophrenia risk. These two 
issues, along with lack of consistency of CNV validation across test sites and/or across test 
assays present obstacles to wide-spread clinical use of schizophrenia risk screening using CNVs 
called from microarray SNP intensities.   
Although all four of these loci showed locus-specific significance, none of the loci 
achieved genome-wide significance for difference between cases and controls except for COX5B 
(Table 4). Low effect size and rarity of CNVs at specific loci decrease analytical power for 
finding associations between loci and schizophrenia risk. Meta-analysis of multiple studies may 
be necessary to achieve genome-wide significance for many schizophrenia-risk CNV loci, since 
many of the loci with hypothetical risk discovered to date tend to be rare
44
. 
 One common CNV, ERBB4, was evaluated by real-time qPCR in both ICCSS and 
IHDSF samples and CNV deletion frequencies were compared with Trinity Biobank and North 
American control populations. The ERBB4 deletion frequency was significantly different when 
comparing the Irish family to the North American controls. The deletion frequency was not 
significantly different when comparing the Irish controls to the Irish singleton or the Irish family 
samples. Because the deletion frequency did not differ when population-matched controls were 
compared to family and case samples this suggests that population stratification was the cause of 
the difference seen between Irish family and North American controls, rather than a true 
association of the deletion with schizophrenia.  
The Irish population was chosen as a good candidate for study of schizophrenia due to 
the low immigration and emigration rates compared to North Americans. All affecteds were 
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screened for Irish ethnicity of both maternal and paternal grandparents. CNVs at specific loci, 
like ERBB4, can differ in frequency between different homogeneous populations, such as the 
population found in Ireland, or when compared to heterogeneous populations like North 
Americans, because of founder effects and/or random genetic drift. This study illustrates the 
necessity of comparing affected samples to appropriately matched ethnic controls. 
 
Future Directions 
 Once associations between a CNV locus and schizophrenia risk are shown based on 
difference in frequency between cases and controls, the next step is to discover whether that 
CNV affects expression of a specific gene(s). Although validation in this study was based on 
Taqman probes located within one specific gene, it is possible that the true disease association is 
based on a neighboring gene located within the same CNV. In addition, association with 
schizophrenia risk of gene(s) within a CNV may not necessarily be caused by a difference in 
expression of gene(s) within the CNV itself. One or more regulatory elements within a CNV may 
be affecting a gene(s) at another locus either intra- or inter-chromosomally. Alternatively a CNV 
could influence chromatin structure and/or organization of chromatin within the nucleus, 
affecting many genes at once. 
 To test for expression-specific effects on schizophrenia risk within CNVs in this Irish 
study one could make use of the lymphoblast cell lines that were established for many of the 
samples that were evaluated in this study. mRNA from lymphoblasts could be collected for use 
with real-time qPCR to look for difference in mRNA expression. Cases with and without the 
specific CNV could be compared for mRNA expression differences to see whether the CNV 
itself has a direct effect on expression. Cases with and without the CNV could also be compared 
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to controls with and without the CNV to see whether there is a difference in gene expression 
between cases and controls that occurs regardless of the presence or absence of the CNV. This 
latter experiment could shed light on the overall importance of a specific gene’s expression in 
schizophrenia pathogenesis. It is possible that a gene’s expression could be influenced directly 
by the presence of a CNV, or indirectly, by epigenetics or gene-gene interactions that may be 
shared in common across of subset of individuals with schizophrenia. 
Any genes with mRNA expression differences should also be followed up with western 
blot to look for difference in lymphoblast protein expression. This is important because proteins 
are much closer to the final phenotype output that may or may not influence schizophrenia risk, 
and many mRNA changes do not correlate directly with changes in protein levels. Western blot 
may not be available for all loci due to possible scarcity of adequate locus-specific antibodies; 
risk for loci with only mRNA expression data available should be viewed as weaker evidence 
compared to those with protein expression data.   
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Chapter 3: Discussion 
Current Clinical Practice of Genetic Counseling for Schizophrenia 
 Genetic counseling for schizophrenia risk is currently based on empirical risk estimates 
based on family history (Figure 1), as well as counseling specific for the few rare recurrent high-
risk CNVs identified to date: 1q21.1, 15q13.3, and 22q11 deletions
21,45
. The utility of empirical 
risk is limited somewhat in terms of providing specific risk with the goal of providing 
anticipatory care: it is limited by availability of data for only relatively simple family structure 
with few affected relatives; multiple types of psychiatric disorders can aggregate in families, 
which can’t be used to improve risk estimates with empirical data currently available; and the 
range of risk provided is often large leaving patients with a degree of uncertainty that can 
possibly instill a false sense of security, or conversely, instill anxiety from perceived heightened 
risk of developing schizophrenia
45
. Despite these difficulties a positive family history remains 
the single greatest risk factor for developing schizophrenia. 
 
Application of CNV-related Risk Estimates in Clinical Practice 
 Currently known CNVs may not impact risk management as much as family history, but 
the clinical utility cannot be ignored. High risk CNVs for schizophrenia are rare and are often 
inherited de novo, but they have a predictable manner of transmission that can be used to provide 
individualized and more exact risk estimates for children of a known carrier
21,45,46
. Chance of 
transmission to offspring is 50%, although parents should be made aware that the expressivity of 
disease, including schizophrenia, can vary greatly even between family members with identical 
variants
21
. 
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Specific penetrance for known recurrent high-risk CNVs vary from as high as 55% for 
22q11.2 deletion, to as low as 2% for 2p16.3 deletion and 15q11.2 deletion
46
. Schizophrenia risk 
from these CNVs is modified by other CNVs, and additional genetic and environmental factors; 
none of these individual CNVs are necessary, or sufficient for disease. The rarity coupled with 
the penetrance of these CNVs makes routine clinical screening for these variants unnecessary 
and not cost effective in the absence of additional clinical features. Clinical screening would be 
suggested if personal or family history is suggestive of features associated with a chromosomal 
disorder that could indicate presence of a pathogenic CNV such as: presence of facial 
dysmorphology, one or more birth defects, intellectual disability, a history of unexplained 
seizures, or another feature in the proband suggestive of a chromosome condition
21
. The most 
promising current application may be for individuals with a known schizophrenia diagnosis: 
previously unidentified pathogenic CNVs have been identified in approximately 2.5% of these 
individuals
21,47
. This could impact medical management outside of their schizophrenia diagnosis, 
as these syndromes are often associated with a number of other phenotypes, some of which may 
be potentially fatal, and/or not easily detectible by routine clinical examination
48
. An example is 
previously undiagnosed congenital heart conditions that can be associated with 22q11.2 deletion. 
About 1% of individuals with schizophrenia also have been shown to have a previously 
undiagnosed 22q11.2 deletion, which can have a major implication on their health outside of 
their psychiatric disorder
47
.  
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Future of Psychiatric Genetic Counseling 
 While individual CNVs may be limited in terms of providing population risk estimates, 
gene pathway and network analysis using CNVs associated with schizophrenia may hold 
promise in expanding our current knowledge of schizophrenia etiology and treatments
2,6,45
. 
Multiple rare CNVs can be grouped by common function or pathways in order to discover 
associations with disease that would be unlikely to be found individually due to small effect size 
and small numbers of individuals affected with the single CNVs
35,49
. Functional genetic groups 
may be used to discover endophenotypes that can predict disease status at an earlier age; 
biomarkers that can identify affected individuals more quickly and easily than current clinical 
diagnosis; or previously unidentified pathogenic CNVs
16,50
.  
 Many clinicians are looking towards opportunities for improving the quality of life for 
individuals affected by schizophrenia by identifying at-risk individuals before onset, or early 
after onset of disease
6,13
. Pre-emptive care can be provided by establishing personalized neuro-
imaging or neuro-cognitive precursors to psychosis; anticipatory care and/or management of 
symptoms in addition to psychosis that may accompany specific risk variants; developing 
tailored risk-estimates to aid in family planning of currently unaffected individuals; and 
attempting to limit environment or gene by environment interactions that further increase risk of 
disease. Known environmental contributors to risk have shown only small-modest effect, but can 
still be useful to minimize risk as much as possible. Factors suggested to be monitored for high-
risk individuals include: substance use avoidance (particularly marijuana use early in life); 
physical and mental exercise, and good nutrition.  
 Cognitive and antipsychotic medication-based treatment of individuals has been shown to 
minimize disease severity and improve quality of life outcomes when implemented early after 
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onset of disease
6
. Aggressive treatment of early signs of schizophrenia can help minimize 
hospitalizations, and disruptions to employment, academic pursuits, and family and social 
interactions.  
 
Summary 
 Ongoing evaluation of rare and common CNVs affecting ERBB4I, ZFYVE20, COX5B, 
PAK7, and CHD1L, is an important step towards identifying and confirming genetic risk factors 
for schizophrenia. Although utility of screening for similar variants in the clinical population 
remains limited, useful insights have been gained from study of rare, higher-risk variants, such as 
22q11 deletion. CNV calling algorithms have improved tremendously with their continued use, 
but validation using real-time qPCR, or another similar method is still needed to confirm 
identification of CNVs. The majority of CNVs identified through calling algorithms did validate 
with qPCR in this study, but at present the reliability and accuracy of these calls is not high 
enough to be used in a clinical setting.  
Future work will see continued exploration of use of multiple CNV-calling algorithms 
and adjustment of calling parameters to optimize accuracy and minimize false negatives
28,30
. 
This may eventually improve CNV calling enough to be able to use this method in a clinical 
setting. Benefits of this method could be quicker turn-around of patient results if the patient has 
had a previous SNP microarray performed, reduced cost of patient care, and potential screening 
of a broader patient population for high risk psychosis-related or other pathogenic CNVs. 
 High-risk individuals for schizophrenia, and other neurodevelopmental disorders, will 
hopefully see continually-increasing benefits from anticipatory care of mental health and other 
health conditions that may accompany specific genetic variants
13,47,51
. They may also look 
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forward to delayed disease onset and/or minimized severity of disease due to earlier diagnosis 
and treatment of disease.  
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